(Total Views: 671)
Posted On: 08/20/2020 9:38:57 PM
Post# of 148918
If Bruce were there it seems like a simple phone call
VANCOUVER, Washington, Aug. 20, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it will conduct its Type A meeting in writing in lieu of a teleconference with the U.S. Food and Drug Administration (FDA). The FDA has agreed to respond to the Company’s questions by September 4, 2020 concerning the additional information the FDA requires to resubmit the Biologics License Application (BLA) for leronlimab as a combination therapy for HIV.
in lieu of a teleconference FDA has agreed to respond to the Company’s questions by September 4,
Bruce could have just sat on a teleconference instead of writing going back and forth for two weeks ?
Am I right ?
VANCOUVER, Washington, Aug. 20, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it will conduct its Type A meeting in writing in lieu of a teleconference with the U.S. Food and Drug Administration (FDA). The FDA has agreed to respond to the Company’s questions by September 4, 2020 concerning the additional information the FDA requires to resubmit the Biologics License Application (BLA) for leronlimab as a combination therapy for HIV. in lieu of a teleconference FDA has agreed to respond to the Company’s questions by September 4,
Bruce could have just sat on a teleconference instead of writing going back and forth for two weeks ?
Am I right ?
(1)
(0)Scroll down for more posts ▼
